MedTrace Logo

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

NCT00991198 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2011-06-08

No results posted yet for this study

Summary

This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical products. Evaluation of the overall skin tolerability of topical dissolved oxygen (safety) utilizing the regimen of products.

Conditions

Interventions

DRUG

Topical oxygen

0.5% concentration of Topical oxygen

DRUG

Topical oxygen

0.25% concentration topical oxygen

DRUG

placebo

no O2

Sponsors & Collaborators

  • Aria Aesthetics Inc.

    lead INDUSTRY

Principal Investigators

  • Zoe D Draelos, MD · Dermatology Consultants Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00991198 on ClinicalTrials.gov